Gastrointestinal (GI) and hepatobiliary disorders affect the structure and function of the GI tract. Many of these disorders often have similar symptoms, such as abdominal pain, cramping, constipation, nausea, bloating, and fatigue. Since multiple disorders can be tied to the same symptoms, it is important for advanced practice nurses to carefully evaluate patients and prescribe a treatment that targets the cause rather than the symptom.<\/p>\n
Once the underlying cause is identified, an appropriate drug therapy plan can be recommended based on medical history and individual patient factors. In this Assignment, you examine a case study of a patient who presents with symptoms of a possible GI\/hepatobiliary disorder, and you design an appropriate drug therapy plan.<\/p>\n
To Prepare<\/strong><\/h2>\n\n- Review the case study assigned by your Instructor for this Assignment<\/li>\n
- Reflect on the patient\u2019s symptoms, medical history, and drugs currently prescribed.<\/li>\n
- Think about a possible diagnosis for the patient. Consider whether the patient has a disorder related to the gastrointestinal and hepatobiliary system or whether the symptoms are the result of a disorder from another system or other factors, such as pregnancy, drugs, or a psychological disorder.<\/li>\n
- Consider an appropriate drug therapy plan based on the patient\u2019s history, diagnosis, and drugs currently prescribed.<\/li>\n<\/ul>\n
By Day 7 of Week 4<\/strong><\/h2>\nWrite<\/strong> a 1-page paper that addresses the following:<\/p>\n\n- Explain your diagnosis for the patient, including your rationale for the diagnosis.<\/li>\n
- Describe an appropriate drug therapy plan based on the patient\u2019s history, diagnosis, and drugs currently prescribed.<\/li>\n
- Justify why you would recommend this drug therapy plan for this patient. Be specific and provide examples.<\/li>\n<\/ul>\n
Reminder:<\/strong> The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. The Sample Paper provided at the Walden Writing Center offers an example of those required elements (available at http:\/\/writingcenter.waldenu.edu\/57.htm<\/a>). All papers submitted must use this formatting.<\/p>\nSubmission and Grading Information<\/strong><\/h2>\nTo submit your completed Assignment for review and grading, do the following:<\/strong><\/p>\n\n- Please save your Assignment using the naming convention \u201cWK4Assgn+last name+first initial.(extension)\u201d as the name.<\/li>\n
- Click the\u00a0Week 4 Assignment Rubric\u00a0<\/strong>to review the Grading Criteria for the Assignment.<\/li>\n
- Click the\u00a0Week 4 Assignment\u00a0<\/strong>link. You will also be able to \u201cView Rubric\u201d for grading criteria from this area.<\/li>\n
- Next, from the Attach File area, click on the\u00a0Browse My Computer<\/strong>\u00a0button. Find the document you saved as \u201cWK4Assgn+last name+first initial.(extension)\u201d and click\u00a0Open<\/strong>.<\/li>\n
- If applicable: From the Plagiarism Tools area, click the checkbox for\u00a0I agree to submit my paper(s) to the Global Reference Database<\/strong>.<\/li>\n
- Click on the\u00a0Submit<\/strong>\u00a0button to complete your submission.<\/li>\n<\/ul>\n
A Sample Answer For the Assignment: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nTitle: <\/strong> NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nThe case study depicts a 46-year-old female patient with a chief complaint of RUQ pain for the last 24 hours. The RUQ pain began an hour after dinner, and she had nausea and vomiting x1 before the pain started. The abdomen is non-distended but has mild tenderness. Lab results revealed a high WBC count and Direct bilirubin. The purpose of this paper is to discuss the patient\u2019s diagnosis and treatment plan.<\/p>\n
Diagnosis<\/strong><\/h2>\nHepatitis A<\/a> is the identified diagnosis for this case. It is caused by the hepatitis A virus (HAV) transmitted via the fecal-oral route through person-to-person contact and ingesting contaminated food or water. The classical presentation in adults includes anorexia, RUQ pain, jaundice, and hyperbilirubinemia (Abutaleb & Kottilil, 2020). Hepatitis A is the presumptive diagnosis based on pertinent positive symptoms of nausea, vomiting, RUQ pain, abdominal tenderness, and high direct bilirubin levels. Besides, an elevated WBC count indicates an underlying infection.<\/p>\nClick here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders <\/strong><\/a>\u00a0<\/span><\/em><\/h3>\n![\"NURS](\"http:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/04\/NURS-6512-Pharmacotherapy-for-Gastrointestinal-and-Hepatobiliary-Disorders-300x154.png\")
NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/figcaption><\/figure>\nDrug Therapy Plan<\/strong><\/h2>\nTreatment of Hepatitis A is usually supportive. I would recommend Acetaminophen 500 mg per oral twice daily to relieve pain. Pain relief is important to promote quality patient care in the acute phase of Hepatitis A (Ntouva et al., 2019). In addition, I would recommend Metoclopramide 10 mg PRN. Metoclopramide is an antiemetic and will be important to alleviate nausea and vomiting. In addition, inactivated Hepatitis A vaccine will be administered for active immunization against diseases associated with HAV (Ntouva et al., 2019).<\/p>\n
Conclusion<\/strong><\/h2>\nThe patient presented with symptoms consistent with Hepatitis A, such as nausea, RUQ pain, mild abdominal tenderness, hyperbilirubinemia, and an elevated WBC count. Hepatitis A could be due to transmission of HAV from contaminated food or water. The treatment plan will include supportive measures such as pain control and alleviating nausea and vomiting using an analgesic and antiemetic.<\/p>\n
\u00a0<\/strong><\/p>\nReferences<\/strong><\/h2>\nAbutaleb, A., & Kottilil, S. (2020). Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention.\u00a0Gastroenterology clinics of North America<\/em>,\u00a049<\/em>(2), 191\u2013199. https:\/\/doi.org\/10.1016\/j.gtc.2020.01.002<\/a><\/p>\nNtouva, A., Sibal, B., Balogun, K., Mandal, S., & Harding, N. (2019). Hepatitis A in primary care: working in partnership for diagnosis, management, and prevention of outbreaks.\u00a0The British journal of general practice : the journal of the Royal College of General Practitioners<\/em>,\u00a069<\/em>(687), 521\u2013522. https:\/\/doi.org\/10.3399\/bjgp19X705965<\/a><\/p>\nA Sample Answer 2 For the Assignment: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nTitle: <\/strong> NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nThe case concerns HL, with nausea, vomiting, and diarrhea. The patient has a history of illicit drug use and a possible Hepatitis C infection. The current drug therapy includes Synthroid 100 mcg, Nifedipine 30 mg, and Prednisone 10 mg. The purpose of this paper is to discuss the diagnosis and drug therapy for this patient.<\/p>\n
Diagnosis<\/strong><\/h2>\nThe patient\u2019s symptoms and medical history are consistent with Hepatitis C, which is caused by Hepatitis C virus (HCV). HCV is transmitted parenterally through contaminated blood from sharing and recycling syringes among drug users, unsafe sexual practices, and unsafe health practices like transfusing unscreened blood (Lazarus et al., 2020). The clinical manifestations of Hepatitis C include nausea, vomiting, anorexia, non-specific upper abdominal discomfort, jaundice, and malaise (Kouroumalis & Voumvouraki, 2022). However, some patients are asymptomatic. Hepatitis C is the presumptive diagnosis owing to the patient\u2019s positive GI symptoms of nausea, vomiting, and diarrhea. In addition, the patient has a history of illicit drug use, which puts him at risk of contracting HCV and a history of Hepatitis C infection.<\/p>\n
Drug Therapy Plan<\/strong><\/h2>\nTreatment guidelines for Hepatitis C recommend treatment with antiviral drugs following the initial diagnosis of the condition. Effective direct-acting antiviral drugs (DAAs) are recommended for hepatitis C to lower the chances of progressing to chronic infection. The patient\u2019s treatment plan will include Ledipasvir\/sofosbuvir (Harvoni) 1 tablet (90 mg\/400 mg) orally once daily for 8 weeks (Chung et al., 2018). The oral combination of Ledipasvir and Sofosbuvir is used to treat adults with chronic hepatitis C, with or without cirrhosis.<\/p>\n
Conclusion<\/strong><\/h2>\nHepatitis C is the presumptive diagnosis for this patient based on the presence of GI symptoms like nausea, vomiting, and diarrhea. The patient may have contracted HCV from sharing syringes, or it could be a chronic infection considering the history of possible Hepatitis C. Treatment will be a combination of Ledipasvir and Sofosbuvir, which is recommended for chronic Hepatitis C.<\/p>\n
\u00a0<\/strong><\/p>\nReferences<\/strong><\/h2>\nChung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E.,Aronsohn, A.I., Bhattacharya, D., Broder, T., Falade-Nwulia, O.O.,& Fontana, R. J. (2018). Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.\u00a0Clinical Infectious Diseases<\/em>. DOI: 10.1093\/cid\/ciy585<\/p>\nKouroumalis, E., & Voumvouraki, A. (2022). Hepatitis C virus: A critical approach to who really needs treatment.\u00a0World journal of hepatology<\/em>,\u00a014<\/em>(1), 1\u201344. https:\/\/doi.org\/10.4254\/wjh.v14.i1.1<\/a><\/p>\n
By Day 7 of Week 4<\/strong><\/h2>\nWrite<\/strong> a 1-page paper that addresses the following:<\/p>\n\n- Explain your diagnosis for the patient, including your rationale for the diagnosis.<\/li>\n
- Describe an appropriate drug therapy plan based on the patient\u2019s history, diagnosis, and drugs currently prescribed.<\/li>\n
- Justify why you would recommend this drug therapy plan for this patient. Be specific and provide examples.<\/li>\n<\/ul>\n
Reminder:<\/strong> The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. The Sample Paper provided at the Walden Writing Center offers an example of those required elements (available at http:\/\/writingcenter.waldenu.edu\/57.htm<\/a>). All papers submitted must use this formatting.<\/p>\nSubmission and Grading Information<\/strong><\/h2>\nTo submit your completed Assignment for review and grading, do the following:<\/strong><\/p>\n\n- Please save your Assignment using the naming convention \u201cWK4Assgn+last name+first initial.(extension)\u201d as the name.<\/li>\n
- Click the\u00a0Week 4 Assignment Rubric\u00a0<\/strong>to review the Grading Criteria for the Assignment.<\/li>\n
- Click the\u00a0Week 4 Assignment\u00a0<\/strong>link. You will also be able to \u201cView Rubric\u201d for grading criteria from this area.<\/li>\n
- Next, from the Attach File area, click on the\u00a0Browse My Computer<\/strong>\u00a0button. Find the document you saved as \u201cWK4Assgn+last name+first initial.(extension)\u201d and click\u00a0Open<\/strong>.<\/li>\n
- If applicable: From the Plagiarism Tools area, click the checkbox for\u00a0I agree to submit my paper(s) to the Global Reference Database<\/strong>.<\/li>\n
- Click on the\u00a0Submit<\/strong>\u00a0button to complete your submission.<\/li>\n<\/ul>\n
A Sample Answer For the Assignment: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nTitle: <\/strong> NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nThe case study depicts a 46-year-old female patient with a chief complaint of RUQ pain for the last 24 hours. The RUQ pain began an hour after dinner, and she had nausea and vomiting x1 before the pain started. The abdomen is non-distended but has mild tenderness. Lab results revealed a high WBC count and Direct bilirubin. The purpose of this paper is to discuss the patient\u2019s diagnosis and treatment plan.<\/p>\n
Diagnosis<\/strong><\/h2>\nHepatitis A<\/a> is the identified diagnosis for this case. It is caused by the hepatitis A virus (HAV) transmitted via the fecal-oral route through person-to-person contact and ingesting contaminated food or water. The classical presentation in adults includes anorexia, RUQ pain, jaundice, and hyperbilirubinemia (Abutaleb & Kottilil, 2020). Hepatitis A is the presumptive diagnosis based on pertinent positive symptoms of nausea, vomiting, RUQ pain, abdominal tenderness, and high direct bilirubin levels. Besides, an elevated WBC count indicates an underlying infection.<\/p>\nClick here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders <\/strong><\/a>\u00a0<\/span><\/em><\/h3>\nNURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/figcaption><\/figure>\nDrug Therapy Plan<\/strong><\/h2>\nTreatment of Hepatitis A is usually supportive. I would recommend Acetaminophen 500 mg per oral twice daily to relieve pain. Pain relief is important to promote quality patient care in the acute phase of Hepatitis A (Ntouva et al., 2019). In addition, I would recommend Metoclopramide 10 mg PRN. Metoclopramide is an antiemetic and will be important to alleviate nausea and vomiting. In addition, inactivated Hepatitis A vaccine will be administered for active immunization against diseases associated with HAV (Ntouva et al., 2019).<\/p>\n
Conclusion<\/strong><\/h2>\nThe patient presented with symptoms consistent with Hepatitis A, such as nausea, RUQ pain, mild abdominal tenderness, hyperbilirubinemia, and an elevated WBC count. Hepatitis A could be due to transmission of HAV from contaminated food or water. The treatment plan will include supportive measures such as pain control and alleviating nausea and vomiting using an analgesic and antiemetic.<\/p>\n
\u00a0<\/strong><\/p>\nReferences<\/strong><\/h2>\nAbutaleb, A., & Kottilil, S. (2020). Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention.\u00a0Gastroenterology clinics of North America<\/em>,\u00a049<\/em>(2), 191\u2013199. https:\/\/doi.org\/10.1016\/j.gtc.2020.01.002<\/a><\/p>\nNtouva, A., Sibal, B., Balogun, K., Mandal, S., & Harding, N. (2019). Hepatitis A in primary care: working in partnership for diagnosis, management, and prevention of outbreaks.\u00a0The British journal of general practice : the journal of the Royal College of General Practitioners<\/em>,\u00a069<\/em>(687), 521\u2013522. https:\/\/doi.org\/10.3399\/bjgp19X705965<\/a><\/p>\nA Sample Answer 2 For the Assignment: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nTitle: <\/strong> NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\nThe case concerns HL, with nausea, vomiting, and diarrhea. The patient has a history of illicit drug use and a possible Hepatitis C infection. The current drug therapy includes Synthroid 100 mcg, Nifedipine 30 mg, and Prednisone 10 mg. The purpose of this paper is to discuss the diagnosis and drug therapy for this patient.<\/p>\n
Diagnosis<\/strong><\/h2>\nThe patient\u2019s symptoms and medical history are consistent with Hepatitis C, which is caused by Hepatitis C virus (HCV). HCV is transmitted parenterally through contaminated blood from sharing and recycling syringes among drug users, unsafe sexual practices, and unsafe health practices like transfusing unscreened blood (Lazarus et al., 2020). The clinical manifestations of Hepatitis C include nausea, vomiting, anorexia, non-specific upper abdominal discomfort, jaundice, and malaise (Kouroumalis & Voumvouraki, 2022). However, some patients are asymptomatic. Hepatitis C is the presumptive diagnosis owing to the patient\u2019s positive GI symptoms of nausea, vomiting, and diarrhea. In addition, the patient has a history of illicit drug use, which puts him at risk of contracting HCV and a history of Hepatitis C infection.<\/p>\n
Drug Therapy Plan<\/strong><\/h2>\nTreatment guidelines for Hepatitis C recommend treatment with antiviral drugs following the initial diagnosis of the condition. Effective direct-acting antiviral drugs (DAAs) are recommended for hepatitis C to lower the chances of progressing to chronic infection. The patient\u2019s treatment plan will include Ledipasvir\/sofosbuvir (Harvoni) 1 tablet (90 mg\/400 mg) orally once daily for 8 weeks (Chung et al., 2018). The oral combination of Ledipasvir and Sofosbuvir is used to treat adults with chronic hepatitis C, with or without cirrhosis.<\/p>\n
Conclusion<\/strong><\/h2>\nHepatitis C is the presumptive diagnosis for this patient based on the presence of GI symptoms like nausea, vomiting, and diarrhea. The patient may have contracted HCV from sharing syringes, or it could be a chronic infection considering the history of possible Hepatitis C. Treatment will be a combination of Ledipasvir and Sofosbuvir, which is recommended for chronic Hepatitis C.<\/p>\n
\u00a0<\/strong><\/p>\nReferences<\/strong><\/h2>\nChung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E.,Aronsohn, A.I., Bhattacharya, D., Broder, T., Falade-Nwulia, O.O.,& Fontana, R. J. (2018). Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.\u00a0Clinical Infectious Diseases<\/em>. DOI: 10.1093\/cid\/ciy585<\/p>\nKouroumalis, E., & Voumvouraki, A. (2022). Hepatitis C virus: A critical approach to who really needs treatment.\u00a0World journal of hepatology<\/em>,\u00a014<\/em>(1), 1\u201344. https:\/\/doi.org\/10.4254\/wjh.v14.i1.1<\/a><\/p>\n
- \n
- Explain your diagnosis for the patient, including your rationale for the diagnosis.<\/li>\n
- Describe an appropriate drug therapy plan based on the patient\u2019s history, diagnosis, and drugs currently prescribed.<\/li>\n
- Justify why you would recommend this drug therapy plan for this patient. Be specific and provide examples.<\/li>\n<\/ul>\n
Reminder:<\/strong> The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. The Sample Paper provided at the Walden Writing Center offers an example of those required elements (available at http:\/\/writingcenter.waldenu.edu\/57.htm<\/a>). All papers submitted must use this formatting.<\/p>\n
Submission and Grading Information<\/strong><\/h2>\n
To submit your completed Assignment for review and grading, do the following:<\/strong><\/p>\n
- \n
- Please save your Assignment using the naming convention \u201cWK4Assgn+last name+first initial.(extension)\u201d as the name.<\/li>\n
- Click the\u00a0Week 4 Assignment Rubric\u00a0<\/strong>to review the Grading Criteria for the Assignment.<\/li>\n
- Click the\u00a0Week 4 Assignment\u00a0<\/strong>link. You will also be able to \u201cView Rubric\u201d for grading criteria from this area.<\/li>\n
- Next, from the Attach File area, click on the\u00a0Browse My Computer<\/strong>\u00a0button. Find the document you saved as \u201cWK4Assgn+last name+first initial.(extension)\u201d and click\u00a0Open<\/strong>.<\/li>\n
- If applicable: From the Plagiarism Tools area, click the checkbox for\u00a0I agree to submit my paper(s) to the Global Reference Database<\/strong>.<\/li>\n
- Click on the\u00a0Submit<\/strong>\u00a0button to complete your submission.<\/li>\n<\/ul>\n
A Sample Answer For the Assignment: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\n
Title: <\/strong> NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\n
The case study depicts a 46-year-old female patient with a chief complaint of RUQ pain for the last 24 hours. The RUQ pain began an hour after dinner, and she had nausea and vomiting x1 before the pain started. The abdomen is non-distended but has mild tenderness. Lab results revealed a high WBC count and Direct bilirubin. The purpose of this paper is to discuss the patient\u2019s diagnosis and treatment plan.<\/p>\n
Diagnosis<\/strong><\/h2>\n
Hepatitis A<\/a> is the identified diagnosis for this case. It is caused by the hepatitis A virus (HAV) transmitted via the fecal-oral route through person-to-person contact and ingesting contaminated food or water. The classical presentation in adults includes anorexia, RUQ pain, jaundice, and hyperbilirubinemia (Abutaleb & Kottilil, 2020). Hepatitis A is the presumptive diagnosis based on pertinent positive symptoms of nausea, vomiting, RUQ pain, abdominal tenderness, and high direct bilirubin levels. Besides, an elevated WBC count indicates an underlying infection.<\/p>\n
Click here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders <\/strong><\/a>\u00a0<\/span><\/em><\/h3>\n
NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/figcaption><\/figure>\n Drug Therapy Plan<\/strong><\/h2>\n
Treatment of Hepatitis A is usually supportive. I would recommend Acetaminophen 500 mg per oral twice daily to relieve pain. Pain relief is important to promote quality patient care in the acute phase of Hepatitis A (Ntouva et al., 2019). In addition, I would recommend Metoclopramide 10 mg PRN. Metoclopramide is an antiemetic and will be important to alleviate nausea and vomiting. In addition, inactivated Hepatitis A vaccine will be administered for active immunization against diseases associated with HAV (Ntouva et al., 2019).<\/p>\n
Conclusion<\/strong><\/h2>\n
The patient presented with symptoms consistent with Hepatitis A, such as nausea, RUQ pain, mild abdominal tenderness, hyperbilirubinemia, and an elevated WBC count. Hepatitis A could be due to transmission of HAV from contaminated food or water. The treatment plan will include supportive measures such as pain control and alleviating nausea and vomiting using an analgesic and antiemetic.<\/p>\n
\u00a0<\/strong><\/p>\n
References<\/strong><\/h2>\n
Abutaleb, A., & Kottilil, S. (2020). Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention.\u00a0Gastroenterology clinics of North America<\/em>,\u00a049<\/em>(2), 191\u2013199. https:\/\/doi.org\/10.1016\/j.gtc.2020.01.002<\/a><\/p>\n
Ntouva, A., Sibal, B., Balogun, K., Mandal, S., & Harding, N. (2019). Hepatitis A in primary care: working in partnership for diagnosis, management, and prevention of outbreaks.\u00a0The British journal of general practice : the journal of the Royal College of General Practitioners<\/em>,\u00a069<\/em>(687), 521\u2013522. https:\/\/doi.org\/10.3399\/bjgp19X705965<\/a><\/p>\n
A Sample Answer 2 For the Assignment: NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\n
Title: <\/strong> NURS 6512 Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders<\/strong><\/h2>\n
The case concerns HL, with nausea, vomiting, and diarrhea. The patient has a history of illicit drug use and a possible Hepatitis C infection. The current drug therapy includes Synthroid 100 mcg, Nifedipine 30 mg, and Prednisone 10 mg. The purpose of this paper is to discuss the diagnosis and drug therapy for this patient.<\/p>\n
Diagnosis<\/strong><\/h2>\n
The patient\u2019s symptoms and medical history are consistent with Hepatitis C, which is caused by Hepatitis C virus (HCV). HCV is transmitted parenterally through contaminated blood from sharing and recycling syringes among drug users, unsafe sexual practices, and unsafe health practices like transfusing unscreened blood (Lazarus et al., 2020). The clinical manifestations of Hepatitis C include nausea, vomiting, anorexia, non-specific upper abdominal discomfort, jaundice, and malaise (Kouroumalis & Voumvouraki, 2022). However, some patients are asymptomatic. Hepatitis C is the presumptive diagnosis owing to the patient\u2019s positive GI symptoms of nausea, vomiting, and diarrhea. In addition, the patient has a history of illicit drug use, which puts him at risk of contracting HCV and a history of Hepatitis C infection.<\/p>\n
Drug Therapy Plan<\/strong><\/h2>\n
Treatment guidelines for Hepatitis C recommend treatment with antiviral drugs following the initial diagnosis of the condition. Effective direct-acting antiviral drugs (DAAs) are recommended for hepatitis C to lower the chances of progressing to chronic infection. The patient\u2019s treatment plan will include Ledipasvir\/sofosbuvir (Harvoni) 1 tablet (90 mg\/400 mg) orally once daily for 8 weeks (Chung et al., 2018). The oral combination of Ledipasvir and Sofosbuvir is used to treat adults with chronic hepatitis C, with or without cirrhosis.<\/p>\n
Conclusion<\/strong><\/h2>\n
Hepatitis C is the presumptive diagnosis for this patient based on the presence of GI symptoms like nausea, vomiting, and diarrhea. The patient may have contracted HCV from sharing syringes, or it could be a chronic infection considering the history of possible Hepatitis C. Treatment will be a combination of Ledipasvir and Sofosbuvir, which is recommended for chronic Hepatitis C.<\/p>\n
\u00a0<\/strong><\/p>\n
References<\/strong><\/h2>\n
Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E.,Aronsohn, A.I., Bhattacharya, D., Broder, T., Falade-Nwulia, O.O.,& Fontana, R. J. (2018). Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.\u00a0Clinical Infectious Diseases<\/em>. DOI: 10.1093\/cid\/ciy585<\/p>\n
Kouroumalis, E., & Voumvouraki, A. (2022). Hepatitis C virus: A critical approach to who really needs treatment.\u00a0World journal of hepatology<\/em>,\u00a014<\/em>(1), 1\u201344. https:\/\/doi.org\/10.4254\/wjh.v14.i1.1<\/a><\/p>\n
- Click the\u00a0Week 4 Assignment\u00a0<\/strong>link. You will also be able to \u201cView Rubric\u201d for grading criteria from this area.<\/li>\n